Since we first learned of the rapid global spread of the coronavirus (COVID-19) the situation continues to evolve at a dizzying pace. LLS has been closely monitoring the fast-changing situation and we understand this is causing confusion and anxiety among our patients and caregivers. We previously shared some important information that blood cancer patients should know about coronavirus which you can read here. You can also visit the CDC website where you can find frequently asked questions.
We all are finding ourselves having to adapt quickly to the new normal. Even here at LLS to protect our staff, blood cancer patients and other constituents in our communities across the country we have made the difficult decision to postpone our in-person fundraising events, and postpone in-person events for patients, caregivers, and healthcare professionals. But please know that LLS remains open for business, although our offices are closed, our staff is working from home. Patients and caregivers should continue to contact our Information Specialists by phone at 800-955-4572 by email or chat by clicking here.
In honor of International Women’s Day on March 8, The Leukemia & Lymphoma Society (LLS) is shining a light on our community of women trailblazers who are leading the way to cancer cures. Malathy Shanmugam, PhD, MS, Winship Cancer Institute of Emory University in Atlanta, is at the forefront of finding new treatments and cures for myeloma. With support from LLS, Dr. Shanmugam is researching an innovative targeted therapy called venetoclax, which is showing promise in multiple myeloma and has proven to be a game changer for some patients with chronic lymphocytic leukemia and acute myeloid leukemia. As March is also Myeloma Awareness Month, we thought it was the perfect opportunity to learn more about Dr. Shanmugam, her cutting edge research and what inspires her.
Some promising news as Myeloma Awareness Month kicks off: the U.S. Food and Drug Administration (FDA) approved today a new therapy for patients with relapsed/refractory multiple myeloma. The approval provides an important new treatment option for patients with difficult-to-treat multiple myeloma.
The new therapy, called isatuximab (Sarclisa®), is approved in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab is a CD38-directed monoclonal antibody that works by helping certain cells in the immune system attack multiple myeloma cells.
LLS research helped support the advancement of this therapy. LLS has helped advance 47 of the 54 blood cancer treatment options approved by the FDA since 2017 to date.
Read the FDA announcement here and learn more about our efforts to lead innovative treatments and care for patients with myeloma on LLS.ORG here.